The 22nd and 23rd May it will be celebrated the IV Poultry Health Course organized by the Centro de Calidad Avícola y Alimentación Animal de la Comunidad de Valencia (CECAV) and the Universidad CEU Cardenal Herrera.
iMICROQ and LAYMATEC are working together on different projects mainly oriented on R&D projects oriented to give complementary solutions of common interest in the area of physical-chemical and microbiological analysis, especially in poultry, cosmetics, pulp and paper, raw materials, food processing and water.
Both companies have signed a collaboration agreement for microbiology analytical services and physical-chemical parameters, with the resources and infrastructure of LAYMATEC in geographical areas where iMicroQ operates directly. Thus, iMicroQ expands its portfolio of services to offer to its customers a comprehensive analytical service using QFAST platform and offering the traditional analytical method.
In a complementary manner, the agreement includes analytical services of physicochemical parameters for other projects that require solutions “tailored” to meet the needs and challenges that each iMicroQ client may have.
iMICROQ achieves an investment agreement to fund the industrialization and commercialization of the Kit QFast Salmonella
On April 17, 2013, iMICROQ signed the new associate agreement and capital increase to finance the development of its business.
”la Caixa”, through its venture capital agency, Caixa Capital Risc, has led an investment of 1.1 million euros in iMICROQ. The financial entity has made the investment thought its fund specialized in biotechnology and medical technologies, Caixa Capital BioMed.
Read more »
iMicroQ has visited the Salón Internacional de Producción Ganadera (FIGAN) 2013, where major international agricultural companies presented the latest technological innovations and business solutions designed to enhance the development of livestock activities and face the future of the market and industry.
Read more »
IMICROQ won the 1st edition of the Competition Opinno Biotech. It has also taken part as a participating company in the Investment Forum, organized in partnership with MIT Enterprise Forum. This Forum has brought together prominent business projects and a select group of venture capital investors specialised in green technologies, biotechnology / nanotechnology, as well as information and communication technologies.
EmTech is the big event of the annual Technology Review, the most prestigious publication of the Massachusetts Institute of Technology (MIT). For the first time, this meeting, held for 12 years in Boston, has a replica in Europe. EmTech Spain arrives to Spain, 26-27 October in Malaga, to bring together business leaders, the most important researchers and technologists, as well as the most innovative entrepreneurs to share knowledge.
Within the framework of the MIT conference EmTech Spain, through the Opinno Biotech Competition, innovative ideas and important projects of young Spanish scientists have been awarded. Thus, this competition has selected the works that have develop new technologies or new applications for existing technologies, and that represent an advance in the field of biotechnology.
IMICROQ has been a finalist company in this 1st edition of the Competition Opinno Biotech. It has also debuted as a participating company in the Investment Forum, organized in partnership with MIT Enterprise Forum. This Forum has brought together prominent business projects and a select group of venture capital investor specializing in green technologies, biotechnology / nanotechnology, as well as information and communication technologies.
The 22nd of June 2011 took place the technical workshop “Control of Salmonella: future prospects: legislation and analytical techniques” organized by IMICROQ, the Aragon and Catalonia Aviary Sanitary Centre (CESAC) and the Research Centre ATIC, University Rovira i Virgili. This event was sponsored by ACC10, Agency for the Support of the Competitiveness of the Catalan Business; ITPSA S.A.: HIPRA; S.P. Veterinary S.A. Adiveter S.L.; ESTEVE Pharmaceutical Group; Anorsa S.A. y Scharlab S.L.
IMICROQ technology has been selected by Genoma España for its INNOCASH program, for the development of technical dossier, as a high economic potential proposal.